Ormutivimab Biosimilar – Anti-G Glycoprotein mAb – Research Grade

Ormutivimab Biosimilar – Anti-G Glycoprotein Monoclonal Antibody Overview

Ormutivimab is a biosimilar monoclonal antibody that specifically targets the G glycoprotein of the rabies virus. Developed as a research-grade molecule, this anti-G glycoprotein antibody offers a high-affinity, reproducible alternative for studying viral entry mechanisms, neutralization pathways, and host-pathogen interactions.

Molecular Structure

The biosimilar Ormutivimab is a recombinant IgG1 monoclonal antibody constructed using hybridoma or recombinant expression systems. It mirrors the original therapeutic structure in amino acid sequence, glycosylation pattern (to the extent possible in non-clinical systems), and binding epitopes. The antibody is composed of two identical heavy chains and two identical light chains, forming a Y-shaped immunoglobulin structure with antigen-binding (Fab) regions and an Fc domain.

The variable regions in the Fab arms are engineered to ensure high specificity toward a conformational epitope on the G glycoprotein of the rabies virus, a critical component of viral attachment and membrane fusion.

Biological Activity and

Mechanism of Action

Ormutivimab binds with high affinity to the G (glycoprotein) envelope protein, which is essential for rabies virus infectivity. The G protein is a key therapeutic target in both prophylactic and therapeutic contexts due to its role in virus-host cell interaction.

Upon binding, Ormutivimab neutralizes the virus by:

• Blocking attachment to host neuronal receptors such as the nicotinic acetylcholine receptor (nAChR) and neural cell adhesion molecule (NCAM)
• Preventing membrane fusion and viral entry
• Triggering immune-mediated clearance through Fc-effector functions such as ADCC (antibody-dependent cellular cytotoxicity) and phagocytosis

Research and Preclinical Applications

This research-grade antibody is widely used in:

• Neutralization assays for studying rabies viral inhibition mechanisms
• Epitope mapping and structural biology studies of glycoprotein–antibody interactions
• Animal models evaluating passive immunization strategies
• Comparative studies between biosimilars and original anti-rabies biologics
• Assay development for diagnostics targeting rabies G protein

Its consistent performance and known binding profile make Ormutivimab an excellent tool for academic, diagnostic, and early-stage preclinical research involving rabies virus and antibody engineering.

Advantages of Using Ormutivimab Biosimilar

• High batch-to-batch consistency
• Cost-effective alternative to clinical-grade antibodies
• Validated specificity for rabies G glycoprotein
• Suitable for in vitro and in vivo use (non-human)

Conclusion

Ormutivimab Biosimilar offers researchers a powerful tool to explore viral immunology, advance rabies virus studies, and evaluate antibody-based therapeutics targeting the G glycoprotein. While not intended for therapeutic use in humans, its value in the laboratory as a model antibody and reference for therapeutic target validation is substantial.